ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2088

When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis

Louise Murphy1, Kristina Theis 2, Dana Guglielmo 2, Kamil Barbour 3, Charles Helmick 2 and Janet Croft 2, 1Centers for Disease Control and Prevention, Division of Population Health, Atlanta, 2Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, 3Centers for Disease Control and Prevention, Atlanta

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Chronic pain and population studies

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Pain is a hallmark of arthritis. Despite growing attention to chronic pain (CP), surprisingly little is known about its magnitude and impact among the 54.4 million US adults with arthritis. We studied two pain outcomes, CP and high impact chronic pain (HICP), among US adults age ≥18 years with a focus on those with arthritis.

Methods: We analyzed 2016/2017 data from the population-based US National Health Interview Survey (NHIS) (59, 696 participants). Arthritis was a “yes” (n=16,732) to “Have you ever been told by a doctor or other health professional that you have some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia?” We calculated crude and age-standardized prevalence of CP (pain most/all days in past 6 months) and HICP (CP that limited life or work activities on most/all days in the past 6 months) among US adults overall and by arthritis status. Then, among all US adults, we estimated the multivariable-adjusted association with prevalence ratios (PR) from logistic regression models between each pain outcome and 14 chronic conditions and 6 socio-demographic characteristics. Finally, we calculated CP and HICP prevalence among adults with arthritis across socio-demographic characteristics, health status, and comorbidities.

Results: Crude CP and HICP prevalence among adults with arthritis was 48.4% and 21.6%, respectively (Figure). Both CP and HICP age-standardized prevalence for adults with arthritis was higher than for US adults overall and those without arthritis, respectively (CP=48.5%, 19.2%, and 11.6%; HICP=21.4%, 7.1%, and 3.3%). In multivariable modelling, across all conditions examined, arthritis had the second strongest association with CP (PR=2.1; 95% CI=2.0-2.2) and HICP (PR=2.2; 95% CI=2.1-2.4); low back pain was the most strongly associated with CP (PR=2.2; 95% CI [confidence interval]=2.1-2.3) and HICP (PR=2.3; 95% CI=2.1-2.5) (Table). Among adults with arthritis, 5 subgroups had CP prevalence >70%: serious psychological distress (82.2%), unable to work/disabled (80.8%), neck pain (74.1%), fair/poor self-rated health (73.3%), and arthritis-attributable activity limitations (71.7%). At least 40% in these 5 subgroups had HICP: unable to work/disabled (63.4%), serious psychological distress (59.7%), American Indian/Alaskan Native (43.0%), kidney disease (41.1%), and neck pain (40.3%).

Conclusion: Approximately one in two and one in five adults with arthritis live with CP and HICP, respectively; among them, both CP and HICP prevalence was even higher for those living with other challenges, including work disability and psychological distress. Despite unknown temporality, our study results combined with clinical evidence suggests that arthritis may be a leading cause of CP and HICP among US adults. Integrated approaches to pain management that include evidence-based non-pharmacologic strategies (e.g., cognitive behavioral therapy, physical activity, and self-management education) can reduce CP and its adverse effects, such as psychological distress, and may help reduce prescribed opioid use.


Figure


Table


Disclosure: L. Murphy, None; K. Theis, None; D. Guglielmo, None; K. Barbour, None; C. Helmick, None; J. Croft, None.

To cite this abstract in AMA style:

Murphy L, Theis K, Guglielmo D, Barbour K, Helmick C, Croft J. When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/when-it-just-wont-stop-chronic-pain-and-high-impact-chronic-pain-among-u-s-adults-with-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/when-it-just-wont-stop-chronic-pain-and-high-impact-chronic-pain-among-u-s-adults-with-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology